Kuehn Law Encourages UMBF, ALIM, TBNK, and BEST Investors to Contact Law Firm

Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Alimera Sciences, Inc. has agreed to sell to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing, plus a non-tradable contingent value right for up to $0.50 per share if specific net revenue targets are met in 2026 and 2027. BEST, Inc. has entered into a definitive agreement to merge with BEST Global Partners an ...